Drug or treatment

Datopotamab clinical trials

• 10Clinical trials
• 1New in 30 days
• 24Countries

Newest trials

All recruiting trials (10)

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• Datopotamab deruxtecan versus docetaxel for previously treated TROP2-positive advanced non-squamous NSCLC

  This trial tests whether datopotamab deruxtecan works better than docetaxel for people with TROP2-positive advanced or metastatic non-squamous NSCLC who have already received prior therapy and do not have actionable genomic alterations.

  Recruiting at 182 sites Phase 3 AstraZeneca · Chandler, Arizona and 205 other locations · NCT07291037

• Preventing Dato‑DXd–related mouth sores with dexamethasone mouthwash

  This study will see if using an alcohol‑free dexamethasone mouthwash can prevent mouth sores in adults with advanced breast cancer or non‑squamous non‑small cell lung cancer who are receiving datopotumab deruxtecan.

  Recruiting Phase 2 Brown University · Providence, Rhode Island · NCT06974604

• Datopotamab deruxtecan with or without durvalumab for PD-L1–negative metastatic triple-negative breast cancer

  This will see if adding durvalumab to datopotamab deruxtecan helps people with PD-L1–negative advanced or metastatic triple-negative breast cancer live longer without their disease getting worse.

  Recruiting Phase 2 Queen Mary University of London · London and 1 other locations · NCT06954480

• Datopotamab-deruxtecan with carboplatin and pembrolizumab for treatment‑naive NSCLC that has spread to the brain

  This trial will try giving datopotamab-deruxtecan together with carboplatin and pembrolizumab to adults with metastatic non‑small cell lung cancer that has spread to the brain and has no targetable mutations.

  Recruiting at 13 sites Phase 2 Latin American Cooperative Oncology Group · Fortaleza, Ceará and 12 other locations · NCT06822543

• Treatment for HER2-negative metastatic breast cancer using two investigational drugs

  This study is testing if using two new drugs one after the other can help people with HER2-negative metastatic breast cancer live longer and feel better.

  Recruiting at 10 sites Phase 2 Dana-Farber Cancer Institute · Birmingham, Alabama and 10 other locations · NCT06533826

• First-line treatment for advanced non-squamous lung cancer with high PD-L1 expression

  This study is testing a new combination treatment for patients with advanced non-squamous lung cancer that has high PD-L1 levels to see if it works better than current options.

  Recruiting at 236 sites Phase 3 AstraZeneca · Anchorage, Alaska and 289 other locations · NCT06357533

• First-line treatment for advanced non-small cell lung cancer with osimertinib and datopotamab deruxtecan

  This study is testing if combining two treatments, osimertinib and datopotamab deruxtecan, can help people with advanced non-small cell lung cancer that has certain mutations feel better compared to just using osimertinib alone.

  Recruiting at 133 sites Phase 3 AstraZeneca · Fountain Valley, California and 166 other locations · NCT06350097

• Datopotamab deruxtecan for treating breast cancer that has spread to the brain

  This study is testing a new drug called datopotamab deruxtecan to see if it can help people with HER2-negative breast cancer that has spread to the brain.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT06176261

• Evaluating Datopotamab Deruxtecan for Advanced Solid Tumours

  This study is testing a new cancer treatment called Datopotamab Deruxtecan to see how well it works and how safe it is for people with advanced solid tumors like ovarian and colorectal cancers.

  Recruiting at 56 sites Phase 2 AstraZeneca · Los Angeles, California and 95 other locations · NCT05489211

Quick answers

How many clinical trials of Datopotamab are recruiting right now?

10, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (7 trials), Taiwan (5 trials), Brazil (4 trials), Canada (4 trials), China (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 6, Phase 3: 3, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →